The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies

The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch
                              of Novel Therapies

Despite Strong Genericization of the Dyslipidemia Market, Statins Will Remain
the Sales-Leading Drug Class Through 2022, According to a New Report from
Decision Resources

PR Newswire

BURLINGTON, Mass., Aug. 20, 2013

BURLINGTON, Mass., Aug. 20, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that the dyslipidemia market will grow to just over
$31 billion in 2022, at an annual rate of 2 percent from 2012. The launch of
antidyslipidemic agents from two novel drug classes–PCSK9 and CETP
inhibitors–will be the primary drivers of market growth, off-setting the
voracious genericization that has and will continue to impact the market
through 2022.

The Pharmacor advisory service entitled Dyslipidemia  finds that, despite
continued generic erosion of Pfizer's Lipitor (atorvastatin) and the launch of
generic versions of AstraZeneca's/Shionogi's Crestor and Merck's ezetimibe
franchise—Zetia (ezetimibe), Vytorin (ezetimibe/simvastatin), Liptruzet
(ezetimibe/atorvastatin)—statins will remain the sales-leading drug class
through 2022.

"The failure of non-statin drugs to demonstrate a cardiovascular outcomes
benefit above that of statin therapy in clinical trial has further cemented
the first-line status of the statin class, and eroded physician willingness to
address residual risk by normalizing non-LDL lipids," said Decision Resources
Analyst Pam Narang, M.Sc., Ph.D. "Decision Resources expects the recent
outcome of the HPS2-THRIVE study that investigated the effect of HDL-C raising
with Merck's Tredaptive to spell the end for niacin-based drugs. Yet we see
continued physician optimism for CETP inhibitors, which also primarily target
HDL-C. While this enthusiasm is driven by their additional LDL-C lowering
ability, the pendulum appears to be swinging back to LDL-C as the most robust
modifiable dyslipidemia target, according to experts we interviewed."

The report findings also reveal the result of the outcomes trial IMPROVE-IT
for ezetimibe is the most highly anticipated near-term event in the
dyslipidemia market. Positive data from this trial will have a significant
effect on physician prescribing and provide further validation of the LDL-C
hypothesis, which will impact emerging LDL-C lowering agents such as the PCSK9
inhibitors. These agents will initially target the most high-risk patients.
Launching in a specific patient subpopulation with the intention of gaining a
broader label is an established development strategy, and one previously
employed for prescription omega-3 fatty acids, Amarin's Vascepa and
AstraZeneca's Epanova.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE Decision Resources

Website: http://www.decisionresources.com
 
Press spacebar to pause and continue. Press esc to stop.